SCHEMBL2511534

SCHEMBL2511534

Cc1c([N+](=O)[O-])cc[n+]([O-])c1-c1c(C)c([N+](=O)[O-])cc[n+]1[O-]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.52
TSHR P16473 6/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HSD17B10 Q99714 2/20 0.41
CYP3A4 P08684 2/20 0.39
MAPT P10636 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 2/20 0.38
S1PR4 O95977 1/20 0.38
S1PR1 P21453 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CYP1A2 P05177 1/20 0.36
RECQL P46063 1/20 0.36
GPR35 Q9HC97 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL539611 0.84 TDP1 (0.52) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL29440728 0.84 TDP1 (0.52) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL27331521 0.81 TDP1 (0.48) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL21644467 0.81 TDP1 (0.48) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL28224311 0.81 TDP1 (0.48) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL9784653 0.77 TDP1 (0.44) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL26104895 0.74 TSHR (0.44) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL192328 0.73 TDP1 (0.46) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL31329852 0.73 CYP1A2 (0.42) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4
SCHEMBL27875406 0.73 CYP1A2 (0.42) TDP1TSHRSMN1; SMN2HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034947-B2 Pyridine oxide compound, and process for producing carboxylic acid derivative and optically active carboxylic acid derivative with the use of the same TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2011-10-11 US disclosed
US-20090062548-A1 NOVEL PYRIDINE OXIDE COMPOUND, AND PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND OPTICALLY ACTIVE CARBOXYLIC ACID DERIVATIVE WITH THE USE OF THE SAME TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062548-A1 NOVEL PYRIDINE OXIDE COMPOUND, AND PROCESS FOR PRODUCING CARBOXYLIC ACID DERIVATIVE AND OPTICALLY ACTIVE CARBOXYLIC ACID DERIVATIVE WITH THE USE OF THE SAME ADH5, ADH1A, ADH1C TDP1 4686/4885TSHR 1067/4885SMN1; SMN2 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.